NCT07144410

Brief Summary

Intrathecal opioids are frequently combined with local anesthetics to optimize spinal anesthesia for cesarean delivery. Fentanyl, a lipophilic opioid, offers rapid onset and enhanced intraoperative analgesia. However, its postoperative analgesic duration is limited, but in contrast, morphine, a hydrophilic opioid, provides prolonged postoperative pain control but has a slower onset and a higher incidence of adverse effects, notably nausea and vomiting. This prospective, randomized, double-blind, parallel study enrolled 180 parturients scheduled for elective cesarean section, all receiving spinal anesthesia with hyperbaric bupivacaine (7.5-10 mg, adjusted to height) plus either intrathecal fentanyl 25 µg (F group) or intrathecal morphine 100 µg and fentanyl 25µg (M+F group). Primary outcomes include intraoperative and postoperative pain scores, systemic opioid consumption, and patient satisfaction, while secondary outcomes assess the incidence of opioid-related side effects.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
180

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Aug 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2025

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

August 14, 2025

Completed
13 days until next milestone

First Posted

Study publicly available on registry

August 27, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2025

Completed
Last Updated

August 27, 2025

Status Verified

August 1, 2025

Enrollment Period

2 months

First QC Date

August 14, 2025

Last Update Submit

August 23, 2025

Conditions

Keywords

spinal anaesthesiaelective caesarean sectionintrathecal opioidsfentanylmorphineopioids side effectsanalgesiafentanyl and morphine

Outcome Measures

Primary Outcomes (2)

  • Assessing the perioperative analgesic efficacy

    Pain intensity will be evaluated using the Numeric Pain Scale, with scores obtained at the time of skin incision, at the end of surgery, and at 4h, 6h, 12h, 24h, 48h, and 72 hours postoperatively; AUE72h (sum pain intensity differences area over 72 hours) and SPID72h (time-weighted sum pain intensity differences over 72 hours). Assessments will be conducted both at rest and during mobilization. The pain scores according to the Numeric Pain Scale will be rated between 0 and 10, meaning 0 - no pain and 10 - the worst pain imaginable

    6 months

  • Assessing the degree of patient's satisfaction

    Assessing the degree of satisfaction on a five point scale with the highest rate as being "completely satisfied", followed by "satisfied", "so so", "unsatisfied" and "completely unsatisfied"

    6 months

Secondary Outcomes (2)

  • Incidence of Additional Opioid-Related Adverse Effects

    6 months

  • Incidence and Severity of Pruritus

    6 months

Study Arms (2)

Fentanyl, Morphine and Bupivacaine

Pregnant patients scheduled for C-section that received a spinal anaesthesia mixture of Fentanyl, Morphine and Bupivacaine

Drug: fentanyl + morphine

Fentanyl and Bupivacaine

Pregnant patients scheduled for C-section that received a spinal anaesthesia mixture of Fentanyl and Bupivacaine

Drug: fentanyl

Interventions

The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.

Also known as: plus bupivacaine
Fentanyl, Morphine and Bupivacaine

The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.

Also known as: plus bupivacaine
Fentanyl and Bupivacaine

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPregnant women
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

The subjects of the study will be selected from the pregnant patients of Oradea Pelican Clinic Hospital.

You may qualify if:

  • American Society of Anesthesiologists (ASA) physical status class I-II.
  • Absence of significant past medical conditions.
  • No documented hypersensitivity to any study drug.
  • No history of chronic pain syndromes or regular analgesic consumption.
  • No anxiety or depressive disorders diagnosis.
  • Body weight ≥ 50 kg.
  • Scheduled for elective cesarean delivery.
  • Single fetus.

You may not qualify if:

  • Patient refusal.
  • Contraindication of spinal anaesthesia.
  • Conversion from a natural delivery with or without an epidural anaesthesia started.
  • History of substance abuse or drug dependence.
  • Presence of acute or chronic fetal distress.
  • Preeclampsia.
  • Allergic reaction occurring after enrollment.
  • Refusal to receive protocol-specified analgesics or medications.
  • Requirement for surgical re-intervention within 72 hours postoperatively.
  • Previous administration of opioids or other central nervous system depressants prior to intervention.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Oradea, Pelican Clinic Hospital

Oradea, Bihor County, 410505, Romania

Location

MeSH Terms

Conditions

Agnosia

Interventions

FentanylMorphineBupivacaine

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Aurel Mohan, MD, PhD

    Head of Surgery Department of Medicine and Pharmacy Faculty of Oradea

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 14, 2025

First Posted

August 27, 2025

Study Start

August 1, 2025

Primary Completion

October 1, 2025

Study Completion

October 1, 2025

Last Updated

August 27, 2025

Record last verified: 2025-08

Locations